Latest news with #VizOncologySuite
Business Wire
6 days ago
- Business
- Business Wire
Viz.ai Launches New Strategic Alliance to Accelerate Timely Diagnosis and Deliver AI-Powered Precision Care for Patients with Cancer
SAN FRANCISCO--(BUSINESS WIRE)-- the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of a new multi-year collaboration with Novartis aimed at transforming cancer care through the development of proprietary AI-powered workflows within the Viz Oncology Suite. This strategic alliance will focus on improving the identification and stratification of patients diagnosed with prostate and breast cancers based on key risk factors, accelerating access to guideline-based precision treatments. For patients with cancer, every day matters. Yet too often, diagnosis and treatment are delayed by fragmented systems, manual reviews, and complex care journeys. These inefficiencies can lead to missed diagnoses, delayed access to life-extending therapies, and worse outcomes. This collaboration aims to address that, using AI to help ensure patients are surfaced and treated earlier, with care that's timely, coordinated, and personalized. 'We are excited to be partnering with Novartis, an innovative medicines company and a leader in oncology, to accelerate access to timely, guideline-based care for patients facing prostate and breast cancer,' said Chris Mansi, MD, CEO and co-founder of 'This collaboration is part of our broader strategic expansion into oncology, furthering mission to fundamentally transform healthcare through intelligent care coordination.' As part of the collaboration will be developing two new AI-powered solutions: Viz Prostate Cancer, designed to streamline the identification of eligible patients for guideline-based treatment and support timely referrals to an appropriate specialist. Only one in four patients receives guideline-recommended therapy for prostate cancer, and thousands of patients with advanced disease who are eligible for potential life-extending treatments are never identified. 1,2 Viz Breast Cancer, designed to support breast oncologists by automating patient review, aggregating risk-relevant data, surfacing therapeutic guidelines, and facilitating coordination among multidisciplinary care teams. Breast cancer is the most widely diagnosed cancer in the United States, with patient care journeys that are complex, time-consuming, and often fragmented. 3 'Earlier diagnosis and interventions can positively impact patient outcomes. At Novartis, we lead the industry in fostering bold partnerships and initiatives that support early screening and diagnosis; we are also leveraging innovative, data-driven technologies to help connect patients with appropriate care as quickly as possible," said Rodney Gillespie, Head of Oncology, Novartis US. "By sharing key insights with we will develop AI-powered solutions to quickly help reach patients who could benefit from guideline-based targeted treatments for prostate and breast cancer, helping significantly expedite their care.' 'Too often, patients with cancer are identified late or fall through the cracks of an increasingly complex care system,' said Ethan M. Basch, MD, Chief of Oncology and Cancer Hospital Physician-in-Chief at UNC. 'AI-powered tools bring the potential to optimize how we detect, triage, and treat cancer—by delivering the right care, to the right patient, at the right time.' With this collaboration and expansion into oncology, is building on its commitment to create a connected, intelligent healthcare AI layer that delivers better care for every patient, everywhere. Learn more about Viz Oncology by visiting About Inc. is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700+ hospitals and health systems in the U.S. and Europe. The AI-powered One® is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit References Goebell PJ, Raina R, Chen SL, et al. Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia. Future Oncol. 2024;20(11):903-918. doi:10.2217/fon-2023-0814 Reynolds S. Many men with metastatic prostate cancer are not getting the recommended treatments, study finds. Cancer Currents Blog. February 18, 2025. Accessed April 21, 2025. American Cancer Society. How common is breast cancer? American Cancer Society. Accessed April 21, 2025.
Yahoo
28-05-2025
- Business
- Yahoo
Viz.ai Expands AI Cancer Care Tools with AI-Powered Viz Oncology™ Suite
Comprehensive suite of solutions designed to empower oncology care teams, accelerating patient diagnosis and treatment strategic expansion into new oncology service line, enhances the company's leadership in stroke care, cardiology, trauma, and radiology SAN FRANCISCO, May 28, 2025--(BUSINESS WIRE)-- the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of the Viz Oncology™ Suite, a transformative platform designed to accelerate access to life-saving cancer care. This marks a strategic expansion of proven capabilities into oncology, building on the company's success in stroke, cardiology, respiratory, and radiology. "Cancer remains one of the most urgent and complex clinical challenges in medicine today, is proud to bring our advanced AI platform to support oncology teams," said Chris Mansi, MD, CEO and co-founder of "This expansion aligns with our mission to increase access to lifesaving treatments. We bring our proven success in time-sensitive specialties to oncology, identifying patients faster, getting them to the right specialist sooner and streamlining clinical workflow. With the Viz Oncology Suite, we are enabling a similar transformation in cancer care – one that is patient-centered, data-driven, and scalable." Cancer care is inherently complex – requiring the integration of vast amounts of longitudinal data, cross-specialty collaboration, and timely, guideline-directed interventions. Despite this complexity, oncology care pathways remain fragmented and highly manual, often leading to delays and variability in care that can compromise patient outcomes—especially outside of major cancer centers where resources and specialist access may be more limited. The Viz Oncology Suite addresses this critical gap by delivering an end-to-end AI solution that streamlines coordination, surfaces high-risk patients earlier, and helps ensure that every patient has timely access to the care they need. "Tools like the Viz Oncology Suite will bring AI-driven intelligence and automation to the front lines of oncology, enabling clinicians to identify and engage the right patients faster," said Sara Nunnery, MD, MSCI, Director of Breast Cancer Research at Tennessee Oncology. "By streamlining complex oncology workflows and care team coordination, this technology has the potential to enhance care delivery and ultimately improve outcomes for our patients in the community." The oncology service line represents one of the largest and fastest-growing areas in healthcare, projected to nearly double in revenue over the next decade. Yet, clinical need far outweighs the capacity of current systems. The Viz Oncology Suite helps close this gap, giving providers the tools to deliver timely, guideline-directed care and empowering them to manage a growing volume of complex cases with greater efficiency and precision. About Inc. is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700+ hospitals and health systems in the U.S. and Europe. The AI-powered One® is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit View source version on Contacts Media Contacts Carolyn Daniel Yunger / Daniel /
Business Wire
28-05-2025
- Business
- Business Wire
Viz.ai Expands AI Cancer Care Tools with AI-Powered Viz Oncology™ Suite
SAN FRANCISCO--(BUSINESS WIRE)-- the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of the Viz Oncology™ Suite, a transformative platform designed to accelerate access to life-saving cancer care. This marks a strategic expansion of proven capabilities into oncology, building on the company's success in stroke, cardiology, respiratory, and radiology. 'Cancer remains one of the most urgent and complex clinical challenges in medicine today, is proud to bring our advanced AI platform to support oncology teams,' said Chris Mansi, MD, CEO and co-founder of 'This expansion aligns with our mission to increase access to lifesaving treatments. We bring our proven success in time-sensitive specialties to oncology, identifying patients faster, getting them to the right specialist sooner and streamlining clinical workflow. With the Viz Oncology Suite, we are enabling a similar transformation in cancer care – one that is patient-centered, data-driven, and scalable.' Cancer care is inherently complex – requiring the integration of vast amounts of longitudinal data, cross-specialty collaboration, and timely, guideline-directed interventions. Despite this complexity, oncology care pathways remain fragmented and highly manual, often leading to delays and variability in care that can compromise patient outcomes—especially outside of major cancer centers where resources and specialist access may be more limited. The Viz Oncology Suite addresses this critical gap by delivering an end-to-end AI solution that streamlines coordination, surfaces high-risk patients earlier, and helps ensure that every patient has timely access to the care they need. 'Tools like the Viz Oncology Suite will bring AI-driven intelligence and automation to the front lines of oncology, enabling clinicians to identify and engage the right patients faster,' said Sara Nunnery, MD, MSCI, Director of Breast Cancer Research at Tennessee Oncology. 'By streamlining complex oncology workflows and care team coordination, this technology has the potential to enhance care delivery and ultimately improve outcomes for our patients in the community.' The oncology service line represents one of the largest and fastest-growing areas in healthcare, projected to nearly double in revenue over the next decade. Yet, clinical need far outweighs the capacity of current systems. The Viz Oncology Suite helps close this gap, giving providers the tools to deliver timely, guideline-directed care and empowering them to manage a growing volume of complex cases with greater efficiency and precision. About Inc. is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700+ hospitals and health systems in the U.S. and Europe. The AI-powered One® is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit
